HCSG vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCSG exhibits exceptional financial health, highlighted by a strong Piotroski F-Score of 8/9 and a near-zero Debt/Equity ratio of 0.03. While the current price of $19.49 is a premium to the Graham Number ($11.56), it remains well below the growth-based intrinsic value of $23.90. Explosive year-over-year earnings growth (172.4%) and a low Price-to-Sales ratio (0.75) suggest significant value creation despite thin profit margins. The primary headwinds are bearish insider sentiment and a negative short-term technical trend.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HCSG vs MRK: Head-to-Head Comparison
This page compares Healthcare Services Group, Inc. (HCSG) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.